Gilead’s HIV Franchise Drives Revenue Growth: Is Diversification Needed?

Walking through the Financial District this morning, the air had that particular crispness that often precedes a market shift. It’s a feeling you learn to recognize after two decades of reporting from this concrete canyon – a subtle change in pressure, a collective inhale before the opening bell. My thoughts turned to Gilead Sciences, which had just posted another quarter of robust growth. The numbers were strong, undeniably so. Total revenue up 10% year-over-year to $7.8 billion. But as any seasoned analyst knows, strength can sometimes cast the longest shadow. The story here isn’t just in the top-line figure; it’s in the composition. Nearly three-quarters of that product revenue, a commanding $5.7 billion, flowed from a single source: the company’s HIV franchise.

Let’s be clear. This performance is a testament to commercial execution and scientific endurance. Biktarvy, the cornerstone of Gilead’s HIV treatment empire, delivered $3.8 billion in sales, a steady 7% climb. The newer prevention drug, Yeztugo, is showing remarkable early traction, leaping from $15 million to $232 million in just a year on the strength of its twice-yearly dosing regimen. As Dr. Sarah Reynolds, a healthcare portfolio manager I spoke with last week, noted, “Yeztugo isn’t just capturing market share; it’s potentially expanding the entire prophylaxis market. That’s a qualitatively different kind of growth.” The company’s guidance raise is a direct signal of confidence in this momentum. In the near term, the engines are firing.

Yet, dependence is a precarious strategy in the biopharma world. I’ve watched this play out before. A blockbuster franchise becomes a corporate identity and for years it funds everything – the R&D, the acquisitions, the dividend. Then, inevitably, the patent cliffs appear on the horizon, or a competitor launches a superior therapy, or pricing pressures mount. The Federal Trade Commission and Department of Justice have made their renewed focus on pharmaceutical competition abundantly clear. Gilead’s HIV portfolio, while dominant, is not immune to these forces. The concentration risk is stark: one therapeutic area is carrying the entire enterprise.

Management isn’t blind to this. In fact, their recent actions scream a recognition of the need to diversify. But the cost of that ambition is staggering. The company recorded a quarterly net loss of $11.2 billion, driven almost entirely by acquired R&D expenses from three major deals:

• Arcellx
• Tubulis
• Ouro Medicines
• Cell therapy
• Next-generation oncology
• Trodelvy

These aren’t operational losses; they’re the price of admission into high-stakes fields like cell therapy and next-generation oncology. As one former FDA official turned biotech consultant told me privately, “Gilead is buying lottery tickets at billion-dollar prices. The science is brilliant, but the commercial pathway is unproven.” This tension is evident in the numbers. While Trodelvy, an oncology drug, grows, the broader cell therapy portfolio saw sales decline 14% to $417 million last quarter, squeezed by intense competition.

The liver disease unit offers a glimmer of non-HIV hope, with sales up 10% to $877 million, fueled by Livdelzi. It’s a solid business, but it remains an order of magnitude smaller than the HIV goliath. Building it into a second pillar will take years.

So, what does the smart money think? The hedge fund sentiment, as tracked by databases like Insider Monkey, offers a muted vote of confidence. The number of funds holding Gilead stock nudged up from 71 to 77 in the most recent period. It’s a slight uptick, not a roaring endorsement. It suggests institutional investors see the value but are also weighing the considerable risks on the horizon. They’re watching, as am I, to see if those massive R&D bets can translate into commercial successes that truly move the needle.

From my desk overlooking Broadway, the conclusion is nuanced. Gilead Sciences is a company executing flawlessly on its legacy strength while writing enormous checks for its future. The HIV business is surging, providing a powerful cash flow to fund the transition. But transition it must. The long-term rerating of this stock hinges not on whether Biktarvy can grow another 5% next year, but on whether the company can prove it has a viable, profitable identity beyond a single, albeit phenomenal, franchise. For now, the present is secure, funded by past triumphs. The future, purchased at great expense, remains an experiment in the lab.